Home / Transcripts / S H Kelkar and Company Limited (SHK) · July 29, 2026

S H Kelkar and Company Limited (SHK) Earnings Call Transcript

July 29, 2026

National Stock Exchange of India IN Materials Chemicals earnings 47 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone. Good morning, and welcome to the S H Kelkar a and Company Limited Earnings Conference Call. As a reminder, all participant lines will stay in listen-only mode, and after the presentation ends there will be an opportunity for you to ask questions. <<operator_script>> Please be aware that this conference is being recorded. I will now hand the conference over to Mr. Mit Shah from CDR India for opening remarks. Thank you, and over to you.

Mit Shah executive
#2

Thanks, Ryan. Good afternoon, everyone, and thanks for being with us on S H Kelkar And Company Limited.'s Q1 FY 2027 earnings conference call. Joining us are Mr. Kedar Waze, full-time director and group CEO, Mr. B. Ramakrishnan, CEO, Fragrances Asia and USA, and Mr. Jyoti Chagrawal, Group Chief Financial Officer of the company. We'll start with a few brief opening remarks from management, and after that we'll open the floor for a Q&A session. Before we get going, I should note that some statements on today's call may be forward-looking in nature, and a disclaimer to that effect was included in the earnings presentation shared with you earlier. I'd now like to invite Mr. Vaze to deliver his opening remarks. Thank you, and over to you,

Kedar Vaze executive
#3

Good afternoon, everyone, and thanks for being with us on the S H Kelkar and Company earnings call covering the first quarter of financial year 2027. We're glad to have started the year with a solid performance that held up, along with encouraging revenue growth and better operating profitability. That said, conditions in which we operate still call for caution. Geopolitical developments keep unfolding in West Asia, and energy, freight, and trade volatility in general remain elevated. Right now, the fundamental demand drivers for our industry — consumers' preference for fragrance and taste in personal care, home care, and food categories — are still intact and still growing. Even so, we remain cautious about the overall environment. So rather than trying to predict the environment or macroeconomic growth, our aim is to be ready for rapid shifts. Our long-term priorities haven't changed: deepening customer intimacy, expanding the opportunity pipeline, and investing ahead of demand in R&D and creative development centers as well as manufacturing capabilities. These investments carry near-term costs, but they are what put us in position to win larger briefs, anticipate evolving consumer preferences, and build durable, differentiated positions across categories and new markets, particularly in European and American markets. We're making these investments with discipline and with a clear line of sight to the revenue opportunities they are designed to unlock.

Kedar Vaze executive
#4

Supply continuity and service levels for our current clients stay just as much of a priority for us — and thanks to our proactive planning, we've been able to keep supporting customers with no interruption at all, even with the global supply situation shifting as it has. So with that, I'll pass things to Jagdish, who will walk you through the financial performance in more detail. Jagdish, over to you.

Jagdish Agarwal executive
#5

Thank you, Kedar. Good afternoon, everyone, and thanks for being with us. Consolidated revenue from operations rose 14% Y-o-Y to INR662 crore. The Fragrance segment posted healthy growth, driven by Europe and select international markets—a result we're especially pleased with given the muted consumer environment in some parts of the developed world. The Flavors segment saw strong, broad-based growth across geographies and contributed significantly to the quarter. I'd point out that part of this growth comes from the timing of certain customer orders, so the pace of growth should be read <<inaudible>> on an annualized basis rather than extrapolated from a single quarter. Gross margins are stable year-on-year, helped by a favorable product mix and proactive raw material planning—an outcome we view as satisfactory given volatility in select input prices. Consolidated EBITDA rose 21% to INR89 crore, with the EBITDA margin improving to 13.4% from 12.6% in the corresponding quarter last year, helped by operating leverage on the higher revenue base. Within the Fragrance segment, reported profitability absorbed higher operating expenses tied to continued strengthening of our R&D capabilities and global CDC network. These are deliberate growth-oriented investments, and while they will weigh on segment margins until the corresponding revenues scale up, they are central to the quality and durability of our future growth. The global ingredients business had a softer quarter on lower demand in select export markets, and we are watching this closely.

Jagdish Agarwal executive
#6

Turning to the balance sheet, net debt rose by INR65 crore over the quarter, <<inaudible>> as of June 2026. That stems from two deliberate choices: building strategic inventory so we can guarantee supply to customers amid an uncertain geopolitical landscape, and ongoing deployment of capital into capacity expansion and growth programs. Even as we work through near-term headwinds, our commitment to bringing leverage down over the medium to long term is firm. In the quarter, we booked an exceptional income of roughly INR30 crore tied to the insurance claim from the fire incident. That claim is moving along well, and we anticipate a full settlement before this financial year ends. As we look toward FY ’27, revenue growth may pace unevenly from quarter to quarter, depending on when demand and orders land and on the geopolitical situation. Despite such quarterly swings, the momentum in our business keeps us positioned to achieve double-digit revenue growth with better margins across the full year. Our focus stays on pairing growth with financial discipline via suitable pricing and cost management efforts, stronger cash conversion, and sensible capital allocation. With that, I’d ask the moderator to open the floor for questions. Thank you.

Operator operator
#7

Thanks. Ladies and gentlemen, we'll now start the question-and-answer session. <<operator_script>> Our first question comes from Abhijit Akella at Kotak Institutional Equities. Please go ahead.

Jatin Chawla analyst
#8

Good afternoon, and thanks so much — congrats on the better numbers this quarter. I wanted to dig a bit deeper into a couple of areas. One was revenue growth. First, flavors, as you mentioned, has grown very strongly, though there may be some lumpy orders this quarter. Could you share some outlook for the full year in terms of what your budgets are for that business — specifically revenue growth for the full year — just so we get some perspective on how the rest of the year might look? Then on the fragrances side, the India piece seems a little soft, with revenues flat year-on-year. But is that mainly due to a high base from last year's 1Q? And if so, how are you seeing trends in the India fragrance business? And finally, on the foreign exchange contribution, given the sharp depreciation in the rupee, could you spell out how much that might have contributed to revenue growth this quarter? Thanks.

Kedar Vaze executive
#9

On the revenue side, I'd say that while total revenue for the quarter came in on budget, the internal mix is tilted — flavors are running above budget and the ingredient business is below the project, though overall revenue matches what we expected. As for the quarters still ahead, we anticipate AID will catch up over the course of the year and flavors will normalize. I'd note that flavors brought in INR 112 crore of revenue this quarter, and on a normal basis it would be a ballpark 95. We expect roughly 1-odd month, or 2 3 weeks, of order postponement from clients, given that lead times and shipping times weren't normal. So we've seen an uptick in orders from some of our clients. In July, though, we don't see any decline in that momentum. So demand continues, but I'd look at something like INR95-INR96 crores of flavour sales in quarter one and guesstimate about INR15 crores of preponement from the extra stock buildup in distribution. Yeah, then you had a question on — foreign exchange. I think 9% is like-for-like growth, and then net 5% is our additional FX sales due to the exchange rate.

Kedar Vaze executive
#10

There was a third item from you that I didn't catch.

Jagdish Agarwal executive
#11

Q1 of last year was a pretty strong quarter by comparison, and as we mentioned in quarter four, we made a deliberate choice to pull out of certain low-margin businesses. We also deliberately refrained from overselling to clients—providing only what they actually use on a regular basis, and not accepting any extra advance orders, given the pricing shifts that occurred during the quarter. So as we raised prices, we rationalized the margins. We made certain that we sell the right products to the right people at the right pricing, in a far more disciplined way and, you know, less — with more focus on the business overall, since we weren't confident of having raw material to serve all clients in the first quarter. I think afterward, with our inventory buildup and the current situation, we are now serving almost all the clients.

Jatin Chawla analyst
#12

Thanks. No, that’s genuinely useful context. Appreciate it. My other question was about margins. So one thing is — you mentioned there could be some margin expansion this year together with double-digit revenue growth. Since we reported margins of 13-odd percent this quarter, is there any broad range you’d be comfortable offering for the full year? I mean, would it be, say, 10 to 12, or perhaps a bit higher than that? Anything you’d feel comfortable discussing? I also wanted to ask, should we expect gross margins to stay near these levels — the current levels — given all the volatility in the marketplace? And last, on Flavors, Flavors has been posting very strong margins. So what’s a reasonable, sustainable number to use going forward?

Kedar Vaze executive
#13

Now regarding Favors, I'd say the margins—clearly, rapid expansion has produced a really solid bottom line. We're still seeing that growth. So right now we feel fairly bullish about how the Flavor business is developing. Quarter one, I'd call it very strong. The same kind of momentum may not carry through the rest of the year, yet it's performing extremely well. Repeat demand is there, and new product adoption was good last year. That momentum appears to be carrying over into this year. So Flavors will outperform as the current year vis-a-vis the previous year’s trend, so it is in line. On your bottom-line question, I'd say this quarter isn't unusual in any respect. So, absent any major shifts, we ought to expect a comparable margin and growth. We stay cautious. Demand and the broader geopolitical situation—if it hits various regions of the world, and if it hits certain parts of our business, that would then impact the overall results. Right now, we're seeing strong double-digit growth across the board, and if that double-digit growth holds and stays in place, we should land at a similar margin EBITDA level, at least in absolute terms.

Kedar Vaze executive
#14

It's likely that percentages could move by half a percent here or there, depending on pricing and how sales momentum goes. But there's no way — this quarter is kind of exceptional. This is the normal, baseline quarter.

Jatin Chawla analyst
#15

I really appreciate it. And before I go back into the queue, just one final item, if you don't mind. So, what's the timeline looking like for rebuilding the factory, and for the other expansion as well — could you please give us an update on that? Second, regarding debt, should we be anticipating additional increases as this year goes on? And last, your tax rate appears somewhat elevated. What full-year rate ought we to use? Thanks very much.

Kedar Vaze executive
#16

Jagdish, over to you.

Jagdish Agarwal executive
#17

Alright, so Abhijit, regarding the factory you mentioned, we're expecting an outlay <<inaudible>> in Q3. In all likelihood, we'll shift into the new third quarter. Our debt position will stay roughly the same as it was in June — it might tick up a bit in September — but apart from that, when we speak about the midterm or long term, deleveraging is definitely on the table, and there will be a route to bringing it down. So I don't see that situation staying the same as what we have there. On the effective tax rate you raised, Abhijit — certainly, when we had March '26, the ATR stood at a very high level, and it will moderate as we begin delivering growth across all the other subsidiaries and as we look at overall profitability. Even today, looking at the June quarter, we're at an ATR of roughly 31.5% to 32%. Our goal is for that to come in below 30%, and that's what we're working toward.

Jatin Chawla analyst
#18

Okay, that's clear, and thanks a lot — wishing you all the best.

Operator operator
#19

Thanks. <<operator_script>> Our following question comes from Pranav Tendulkar at Rare Enterprises. The line is yours — please proceed.

Pranav Tendulkar analyst
#20

Hello there, am I coming through clearly?

Kedar Vaze executive
#21

Correct.

Anoop Poojari executive
#22

Sir, so my understanding is that you're not providing similar growth for fragrances on a quarter-on-quarter basis. But what does the opportunity set look like here? Say, 2 years or 3 years down the line, whatever investments we're making, whatever relationships we hold, and this industry is relatively unexplored. So what is the opportunity set here? Could you just take some time to evaluate that or explain it?

Jagdish Agarwal executive
#23

Now, when we consider the size of the fragrance market in, say, just the U.K. and the USA — which are our newest initiatives — that market accounts for roughly 35% to 36% of worldwide demand, compared with India at 5%. So the market we're discussing is 6 to 7 times larger than India's fragrance market. The scale and size of the business are of a different magnitude. So we're directing our first efforts, let's say, into that market. We've seen some traction. We'll keep growing it over the next 2 to 3 years. So the market opportunity is very large. It's basically a $10 billion opportunity, or market size. But we're new. It will take us some time to keep building the relationships and to start building this. But the overall market size is quite large compared with the Indian market, the Asian market.

Pranav Tendulkar analyst
#24

And is that market size actually something we can address with the skill sets we have?

Jagdish Agarwal executive
#25

I mean, in effect over the longer run, yes. What we're going after, I'd say, is that market worth 100 million in these markets, which is the relatively easy or readily accessible part for us as we keep strengthening our R&D capability and our customer engagement. So we've got, let's say, more than sufficient market opportunity for the coming 2 to 3 years. Over the longer term, we've built the platform on innovation, on patents and processes that we're able to take to market. So that's a sustainable advantage we intend to establish in the market and keep growing. So yes, the full 10 billion represents an opportunity for us. Reaching that kind of opportunity space will take 10 years, but the ability to get to all 10 billion is already, in a sense, built in through the patents, through the back-end systems and IP generation.

Pranav Tendulkar analyst
#26

Got it, thank you very much, sir.

Operator operator
#27

Thanks. We’ll take the next question from Shivam Gupta at Trinetra Asset Managers, who is on the line. Please go ahead.

Shivam Gupta analyst
#28

Hello, sir. Thanks for the chance to ask. My question is this: given that customer preferences keep evolving, are you seeing premium fragrances grow more quickly than mass market products? And over the next 2 years, how do you expect that trend to shape your product mix?

Jagdish Agarwal executive
#29

I mean, broadly, when people have more money to spend, they tend to trade up to premium items. That happens normally every year around the world. In periods of elevated inflation — and we think this year will be somewhat subdued on premiumization because of inflation — that trend can soften. Still, by and large, this is a standard pattern in which consumers opt for higher-end goods or move up the ladder. Brands likewise introduce improved versions and items that cost more, and that's just a normal pattern. So it isn't disruptive for us in any way. What we gain from having operated in European markets over the past few years is that we already have products developed for the next wave of products that will arrive in Asia.

Shivam Gupta analyst
#30

Alright.

Jagdish Agarwal executive
#31

In Europe, we're cross-selling earlier versions, and those earlier versions are still trending in Asia.

Shivam Gupta analyst
#32

Alright, sir. For my second question: currently, what share of your revenue is generated by products launched within the past 3 to 5 years?

Jagdish Agarwal executive
#33

Roughly 10% to 11%.

Shivam Gupta analyst
#34

And with that — all right, sir, I have nothing further to add.

Operator operator
#35

Thanks. Our following question comes from Jatin Chawla at RTL Investments. Go right ahead.

Jatin Chawla analyst
#36

Yeah, hi there, good evening, and thank you for taking the question. My first question is this: we've witnessed quite a lot of volatility in raw materials, and with that in mind — you know, since we've maintained some strategic inventory — are we actually seeing any benefit from that in the gross margin? And looking ahead, could there be some negative effect on gross margins once this inventory we're holding begins to run down?

Kedar Vaze executive
#37

So, the way we've set things up, we've got visibility on inventory for 6 months, and our contracts are priced to the client. So we've raised inventory levels to make sure that for the next 4 to 5 months — well, 6 months starting from July — effectively we face no extra cost pressure on raw materials. So every price is locked in either through stock on hand or through contracts in place. So we don't anticipate any major shifts in the profile, the selling price, or the cost structure over the coming 6 months where raw material is concerned. Obviously, we'll keep giving updates on what's happening with raw material month by month, and we've purchased an extra 45 days of inventory into the system so we can pass any big shocks or any major changes along to clients in proper time and avoid taking a hit on the gross margin at our end. So we hold additional inventory that lets us go back to clients well in time and, you know, ask for and push for recalibration of selling prices if that's required.

Jatin Chawla analyst
#38

Understood, understood. A related question on that: if we're confident gross margins can hold, then as revenue scales, shouldn't our EBITDA margins rise? Because your CDC investments are basically finished at this point, so that fixed cost absorption should get better from here on out?

Kedar Vaze executive
#39

Yes, your comment is absolutely right. We are simply not in a position to anticipate or predict what demand will look like, or the demand situation, for the full year. As of now, things look quite in normal range, and as we grow double-digit, plus, our margins will improve. For the full year, we are not confident to predict beyond 2 to 3 months’ time. So it’s a bit early. It’s too uncertain what is happening.. So we don’t want to put out a number which we really don’t know. And if the growth remains as it is, yes, your comment is absolutely right. We do double-digit growth, our margins will be better than the first quarter in the full year. But if we at some point with the currency, with exchange rates and/or growth faltering in any part of the world, then if it has a significant effect on the overall number, then we will have a little bit muted result as a basis.

Jatin Chawla analyst
#40

Thanks. My second question concerns the capacity expansion. Regarding the capex plans for this full year, how much was completed in 1 Q, and it would be useful if you could split that between Europe and India.

Kedar Vaze executive
#41

Roughly INR25 crores was spent in Europe during quarter one. Capex for Europe has now been finished. The plant has been running since May. In quarter two, our capex will keep going on the Vanavate and Vashivali India fragrance projects. We anticipate that most of this investment capex will take place essentially before quarter two ends, and that the Vanavate factory will be operational in quarter three. After that, depending on how things are running and the demand scenario, we have the opportunity either to release the final INR25 crores of capex in quarter four or to push it to quarter one of next year for the Vashivali plant upgradation.

Jatin Chawla analyst
#42

And for Q2, on Vanavate, what's the amount you're planning to spend?

Kedar Vaze executive
#43

During Q2, Vanavate came in at roughly INR 25 crores.

Jatin Chawla analyst
#44

So INR25 crores went out in 1Q, INR25 crores in 2Q, and as for the remaining INR25 crores, you'll make the call on whether that happens this year or next year?

Kedar Vaze executive
#45

No, we'll keep it at roughly INR50 crores. That covers the 3 plants in India.

Jatin Chawla analyst
#46

Understood. Thank you very much. I’ll return to the queue.

Operator operator
#47

Thanks. Our following question comes from Tanish Jhaveri at Boring AMC. The line is yours — go ahead.

Tanish Javeri analyst
#48

Hi there. Yeah, am I coming through okay?

Kedar Vaze executive
#49

Yeah.

Tanish Javeri analyst
#50

Right, so I just wanted to dig a bit deeper on the CDC side of things. When should we start to see a ramp-up at the European subsidiary, and what sort of revenue stream should we be looking for from it, plus an incremental ROCE? What return ratios do you anticipate for the investment we're making in Europe?

Kedar Vaze executive
#51

Looking further out, we expect ROCE of roughly 17% to 18% in the European business. We've recently put money into a big center in Germany, along with the new factory in Almere, so we're basically in a full capex cycle right now. Getting back to the normal trend line will require 3 to 4 years of growth. On the opportunity side, we're putting in about an additional 3 million a year into R&D. And as I mentioned before, the markets we're going after are pretty big. In Europe, we have over $4 billion to $5 billion of new areas where we operate. That $4 billion or $5 billion won't materialize tomorrow morning, of course, but the opportunity space for us really is quite large. So we're confident about growing very rapidly in these markets, since our base is very small.

Tanish Javeri analyst
#52

All right, thanks. And at the group level, what sort of ROE and ROCE are we targeting over the longer term — say, 2 to 3 years out?

Kedar Vaze executive
#53

I'd say we ought to aim for a return on capital above 15%. The target we hold for the long run is 20%, though right now we expect 3 to 5 years of gradual progress toward that 15%, and after that, as sales build in the new initiative areas — you know, once we're past break-even and EBITDA positive — we'll get to that 20% ROC level.

Tanish Javeri analyst
#54

Alright, thanks a lot.

Operator operator
#55

Thanks. Our following question comes from Advait Chowkar at EquiPoise Capital Management. Please go ahead.

Adwait Javkar analyst
#56

Thanks for letting me ask. I’ve got a single question regarding the heavy rain and flooding that hit parts of Gujarat lately, including the Vapi area. Has any of our manufacturing facilities or supply chain operations been affected by that?

Kedar Vaze executive
#57

No,

Adwait Javkar analyst
#58

We don't anticipate any impact, and we aren't expecting any shutdown from this.

Kedar Vaze executive
#59

Nope, up to this point we haven't seen any effect.

Adwait Javkar analyst
#60

Alright, alright. Thanks. Thanks. That's all I have to say.

Operator operator
#61

Thanks. Our following question comes from Ashwin Patel at Intelligent Prosperity Solutions <<inaudible>>. You have the floor.

Abhijit Akella analyst
#62

Thanks for taking my question. I wanted to ask whether your capex cycle is mostly finished. And if it is, what depreciation expense should we expect in FY ’27?

Kedar Vaze executive
#63

At present, we're at roughly INR35 crore each quarter, and after we complete the Vanavate<<inaudible>> capitalization, we'll shift to that level. Our expectation is a run rate in the neighborhood of INR38 crore to INR39 crore per quarter.

Abhijit Akella analyst
#64

Thanks.

Operator operator
#65

Thanks. Our following question comes from Sajal Kapoor of Antifragile Thinking. Go right ahead.

Sajal Kapoor analyst
#66

Hi there, and thanks for the chance to ask. Hello, Kedar. I have a couple of questions. First, what would need to be true 3 years from now for you to be able to say that the investments you've been making to improve KEVA's operating system — and those made over the past decade — were all successful in some way? You mentioned that over the long run we can probably look at 17% to 20% ROCE, but what would give you an early indication that we are trending in that direction?

Kedar Vaze executive
#67

Typically, we’ve got three big new market bets: Germany, the USA, and the U.K. Over the past 2 years—a little more than 2 years—we’ve put quite a lot into those three development centers, with sales, marketing, and the full teams. We’re seeing traction in each one, and what we’re focused on is getting each of those investments to break even on a year-over-year basis in year 3. That’s our milestone. So Germany, which came first, we should expect somewhere between this year and next year to reach a break-even position where we’ve generated enough business to cover the cost. A year later for the USA, and a year later for the U.K. So if we stay on that line in 3 years, where we have EBITDA breakeven on the investments, then we’ll grow from there on our longer-term basis.

Sajal Kapoor analyst
#68

That’s useful, thanks. If you could take away a single limitation today so that Keva’s earnings could double over the next, let’s say, 5 years, which limitation would that be — just one?

Kedar Vaze executive
#69

Revenue doubling in 5 years — is that what you mean?

Sajal Kapoor analyst
#70

Yeah, yeah. So it's a — what's that single constraint? You know, if you were to address that bottleneck or limitation, could you double the top line?

Kedar Vaze executive
#71

The main thing we worry about is big disruptions in the global macro picture. Our business, and the type of business we're in, is very annual — it runs on annual repeat, annuity basis. So once we've got a business, it grows and it sustains itself. The moment we hit a macro event, like the pandemic or something similar, it doesn't just affect the year in which the pandemic occurs — it also affects the pipeline for product launches in the following couple of years. So what we underestimated is the effect of — you know, growth in a subsequent year also depends on product adoptions from the previous year. So as long as we have a consistent macroeconomic situation — even if whatever conditions exist today stay as they are for the next 5 years — we'll be in a very good position to double our revenue and stay on the track that we've outlined. So major changes do affect our business. It takes us much longer than — it's a very complex business, the kind of momentum building involved, and we're not able to cut down R&D and put it back in time. So if there are quick fluctuations, we lose out in that area.

Kedar Vaze executive
#72

That's the key worry or limitation, really. If the environment holds steady — and sure, at the moment the global picture isn't all that favorable for growth, but should it stay the way it is, steady — then we've got far more than enough opportunities and room in which to keep expanding and double the revenue, and stay on our path.

Sajal Kapoor analyst
#73

Great. Thanks — really appreciate it, Kedar. Wishing you all the best. Thank you.

Operator operator
#74

Thanks. We’ll take the next question from Ankur Agarwal, who’s on the line from RC Business House Private Limited. <<inaudible>> Please go ahead.

Abhijit Akella analyst
#75

Hello there. What does promoter holding stand at right now?

Kedar Vaze executive
#76

I believe it's 50 lakh shares, roughly that amount. The borrowing's value against those shares comes to INR30 crore. My understanding is 50 lakh shares.

Abhijit Akella analyst
#77

All right. And what’s the plan for bringing down the debt over the next 1 to 2 years?

Kedar Vaze executive
#78

As Jagdish said, the debt level is going to stay elevated for the coming quarter, at roughly the same levels. While we keep up our capex this quarter and the next one, I think starting in the third quarter it will begin coming down, and what we expect is that each quarter thereafter we'll keep lowering it by about INR25 crores quarter-on-quarter.

Abhijit Akella analyst
#79

Alright, alright, thanks — that's everything from me.

Operator operator
#80

Thanks. <<operator_script>>. Our next question comes from Amit Kumar at Determined Investments. <<inaudible>> The line is yours.

Abhijit Akella analyst
#81

Yes, thanks a lot for giving me the chance. Am I coming through clearly?

Kedar Vaze executive
#82

Yes, go right ahead.

Abhijit Akella analyst
#83

Thank you, yes. Sir, from what I understand about the business, you would typically lock in your pricing with customers at the start of the year. Now, given the disruption we have witnessed on the raw material side — and certainly on pricing, since you were touching a little on availability as well — there was definitely a fair bit of pricing disruption between March to July. So I just wanted to get a sense: given the kind of disrupted raw material environment you have, have you taken any sort of pricing actions during this time between March to till now? And how much of that — given that it's a B2B business — how much of this has been accepted by our customers?

Kedar Vaze executive
#84

So we've adjusted the prices we charge our customers to reflect the cost inflation we ourselves have taken on because of the geopolitical effects. We've passed it through. For almost 95% plus of the clients, we managed to secure reasonable price corrections. And we've put that in place across the board. In cases where certain clients were reluctant, we did not supply until the negotiations were finished. And if you look, that's part of why domestic fragrance sales came in a bit lower than the same quarter last year. But we've been able to pass on the costs successfully, and we've also raised our inventory, so we aren't exposed to future shocks. Essentially, we're committing to clients on delivery quality and supply certainty with the inventory we hold.

Abhijit Akella analyst
#85

Okay, got it. That's all I have to say. Thanks very much.

Operator operator
#86

Thanks. Our next question comes from Bharat Gupta at Fair Value Capital. Please go ahead.

Bharat Gupta analyst
#87

Hi, Kedar. I appreciate the chance to ask. I have a couple of questions. The first concerns the global ingredient business. You said it’s been under watch — are there any major turnarounds we should expect in that segment over the next few years?

Kedar Vaze executive
#88

We couldn't quite catch which business you're referring to.

Bharat Gupta analyst
#89

Regarding the global ingredient business.

Kedar Vaze executive
#90

The global ingredient business, of course, is the one hit far more directly by the supply chain problems that have come up lately. As a result, growth came in muted for the first quarter. We're going to get growth going again, and as we said a few years back, we've taken steps on backward integration and on moving the China supply chain away entirely. Those things are now in place. Sadly, the disruptions opened up a supply gap during this period, so our position isn't strong enough to drive global ingredient growth, yet it's a steady business, and we keep expecting a recovery in the year's second half.

Bharat Gupta analyst
#91

Sure. Regarding the insurance team, I believe we received roughly INR 30-odd crore during the quarter. What's the estimate for how much we've processed for the remainder of the year, like?

Kedar Vaze executive
#92

So I'd say the pending claim amount sits somewhere between INR50 crore and INR55 crore — INR60 crore is what's being claimed. We'll keep pressing the insurers to get that claim settled during this year.

Bharat Gupta analyst
#93

All right. That covers what I had, sir. Many thanks.

Operator operator
#94

Thanks. Our next question comes from Bharat Sheth, who is on the line from Quest Investment Managers Private Limited. <<inaudible>> Go ahead, please.

Analyst analyst
#95

Hey Kedar and Jagdish, congrats on a solid quarter. So Kedar, my question has two parts. First, regarding this Unilever business of ours: how is the ramp-up going, and are we receiving more RFPIs from that same client, or are we bringing in a new client — are we getting any kind of RFPI from a new client? That's one part. And second, on the USA and U/K., you mentioned we're seeing some traction. Could you give some color there, since in Q1 Q4 last year we had also started supplying to the USA?

Kedar Vaze executive
#96

Okay, so as I said, I'll address both parts of your question. With Unilever and the global accounts, we keep engaging—not just with Unilever but with others too. Right now there's a steady flow of projects and developments taking place. In that scenario, we don't have any big breakthrough or major additions to the current portfolio, but work is underway, and things are shifting somewhat on their side, since they're also dealing with pricing pressure on their commodity, and their new product development launches aren't in full swing, particularly in India. Then we discussed the new initiatives with Europe, Germany, the USA, and the U.K. Germany is now really getting going. We've seen consistent traction on the developments happening there and the sales coming out of that. In the USA, we only began gaining traction in Q4 of last year. For the year in the U.S., we expect to bring in at least $1.5 million to $2 million in revenue. So that's a good development. As for the U.K., it's early days. We only started this year, so we need to wait at least 12 to 15 months before substantial business materializes.

Analyst analyst
#97

Alright, great. And for my second question, on flavors: you mentioned you're also in discussions with a larger global account there, so is there any update on how that's progressing now? And second, you said the flavor business should be at a run rate of around INR95 crore starting from Q2 onward — is that a fair way to understand it?

Kedar Vaze executive
#98

I think Q2 could actually be stronger than 95. And my rough estimate at this point — nobody has a precise figure, since client purchases have already taken place. We did 112 in the first quarter. My rough estimate is that roughly INR10 crores to INR15 crores of that would be sales representing extra stock, rather than genuine final consumption. So we might not see that INR15 crore quarter-on-quarter in every quarter. So there's a larger inventory buildup here, especially in the export markets, and in the domestic market as well, given the supply disruption and the price increases. Customers would have built up their inventory levels to capture the benefit of the old price. There is an additional estimated INR15 crores within the INR112 crores, so INR97 crores, INR95 crores is the actual regular business absent any major disruption. That's our rough estimate. So the base is INR95, INR96; quarter two will be better than INR95, INR96, and quarter three will be better than that, and so on, and so forth. We don't expect 112 plus growth in quarter two. That's not what we expect.

Analyst analyst
#99

And then, secondly, I mean, with any global account that we had been working on — so is there any update on that?

Kedar Vaze executive
#100

Nothing major. I believe businesses have begun with certain global nutrition companies and similar ones, but at this moment nothing is substantial or significant. Usually in flavors, products tend to be new introductions. Significant value takes 3 to 4 years to come in.

Analyst analyst
#101

And in Q1, aside from this INR15 crore, on the business side — things like TVA, personal care, beauty, and food and beverage — which of those businesses has been contributing the biggest share?

Kedar Vaze executive
#102

So, honestly, I'd say it's largely business as usual across the board. Our global ingredient business came in below what we expected. We've cut back on supplies. During this period, we have zero certainty when it comes to raw materials. So we've kind of kept things controlled and made certain that all our existing clients get served. And over on the flavor side, sales are above budgeted or above expected levels, which I think will sort of normalize starting in quarter two. There's no segment, no new segment, and nothing outside the ordinary. It's very much a normal quarter with, if I were to sum it up, a normal business, double-digit growth. Flavors outperforming, AID, Global Ingredients under budget, but overall on budget.

Abhijit Akella analyst
#103

Alright, thanks — and best of luck to you.

Kedar Vaze executive
#104

I appreciate that.

Operator operator
#105

Thank you. Ladies and gentlemen — yes, sir, please go ahead. Ladies and gentlemen, we'll treat that as the final question and bring the question and answer session to a close. At this point I hand the conference over to management for their closing comments. Yes, sir, please go ahead. Ladies and gentlemen, we'll treat that as the final question and bring the question and answer session to a close. At this point I hand the conference over to management for their closing comments.

Kedar Vaze executive
#106

Thanks very much. I hope our responses have addressed what you asked. If anything remains unclear or you'd like additional information regarding the company, don't hesitate to reach out to our team or to CDR India. And thanks again for spending part of your day with us on this call.

Operator operator
#107

<<operator_signoff>>

Read the full transcript via the API

You're viewing the first half of this call. Get the complete S H Kelkar and Company Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to S H Kelkar and Company Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.